Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Enveric BiosciencesFRA:SLZ0 30 EV-to-EBIT is 0.20 as of Aug. 26, 2026. GuruFocus rates FRA:SLZ0 with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 380 Biotechnology companies, Enveric Biosciences ranks better than 92.11% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Enveric Biosciences's Enterprise Value for the quarter that ended in Jun. 2026 was €213.49 Mil.
Enveric Biosciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enveric Biosciences EV-to-EBIT Related Terms
Enveric Biosciences EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Enveric Biosciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:SLZ0 vs ALZN, SILO, BGMS: EV-to-EBIT Comparison
For the Biotechnology subindustry, Enveric Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enveric Biosciences EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enveric Biosciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Enveric Biosciences's EV-to-EBIT falls into.
Enveric Biosciences's current Enterprise Value is €-1.51 Mil.
Enveric Biosciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enveric Biosciences (FRA:SLZ0) has a EV-to-EBIT of 0.20 as of Aug. 26, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Enveric Biosciences and its competitors. According to the industry distribution chart, Enveric Biosciences ranks #30 out of 380 companies in the Biotechnology industry, placing it in the top 7.9%.
Is Enveric Biosciences' EV-to-EBIT too high?
Enveric Biosciences' current EV-to-EBIT is 0.20. The Biotechnology industry median EV-to-EBIT is 15.86. Enveric Biosciences' value of 0.20 is 98.7% below this industry median. Based on the distribution chart, Enveric Biosciences ranks #30 out of 380 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Enveric Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Enveric Biosciences' EV-to-EBIT compare to ALZN and SILO?
According to the Biotechnology industry distribution chart, Enveric Biosciences ranks #30 out of 380 companies for EV-to-EBIT. This places Enveric Biosciences in the top 8% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.86. Enveric Biosciences' value of 0.20 is 98.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.86, based on 380 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enveric Biosciences's current EV-to-EBIT of 0.20 is 98.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Enveric Biosciences and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enveric Biosciences's current EV-to-EBIT is 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enveric Biosciences stock overvalued right now?
Enveric Biosciences (FRA:SLZ0) has a current EV-to-EBIT of 0.20. The current EV-to-EBIT is 0.20 and 98.7% below the Biotechnology industry median of 15.86. Enveric Biosciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Enveric Biosciences (FRA:SLZ0), the current EV-to-EBIT is 0.20 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
30GF Score
Get the complete analysis for FRA:SLZ0
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:SLZ0 has been successfully added to your 
